> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CMDE tells Class III device makers where to send trial-protocol questions
- URL: https://chinapharmadesk.com/china-device-trial-protocol-consultation/
- Published: 2026-11-16T14:51:28.000Z
- Updated: 2026-11-17T06:28:34.000Z
- Description: CMDE's Nov 17, 2026 notice tells overseas Class III device applicants to email CMDE and caps ordinary products at two protocol consultations, ahead of the Jan 1, 2027 start under NMPA Notice No. 40.
- Author: Lin Yi
- Tags: Desk brief, Regulation

China’s Center for Medical Device Evaluation (CMDE) on November 17, 2026 issued operating instructions for the Class III device trial-protocol consultation that opens on January 1, 2027\. [The notice, as reproduced the same day by China Pharmaceutical News](https://www.cnpharm.com/c/2026-11-17/1110648.shtml?ref=chinapharmadesk.com), tells overseas applicants to email CMDE and domestic applicants to email a designated provincial address, and it caps ordinary products at two consultations. [NMPA Notice No. 40 of 2026](https://yjj.sh.gov.cn/qtgzwj/20261116/ef654d39357244b4977bc6e067d1081f.html?ref=chinapharmadesk.com), signed November 11 and published November 16, still says an overseas applicant’s China-based agent submits to CMDE. The operating notice does not say that agent step has been removed. The CMDE-hosted original and its three attachments were not retrieved for this update.

The practical addition is a filing address, a dossier list and a numerical cap. A manufacturer can still seek advice on trial design once the product is finalized and the necessary nonclinical work is done, without first holding an innovative-device designation.

## Who sends the file, and how many times

Notice No. 40 and the November 17 instructions do not describe the overseas route in the same words.

| Applicant or product                                    | Notice No. 40, published November 16                                       | November 17 operating notice                                                            |
| ------------------------------------------------------- | -------------------------------------------------------------------------- | --------------------------------------------------------------------------------------- |
| Product already in the innovative-device special review | Existing innovative-device channel to CMDE, with priority handling         | Apply through the innovative-device procedure; the new notice does not restate priority |
| Domestic applicant outside that procedure               | Provincial drug regulator, then referral to CMDE after a preliminary check | Email to the provincial drug regulator’s designated address                             |
| Overseas applicant outside that procedure               | The China-based agent submits to CMDE                                      | Email to CMDE’s designated address                                                      |

The operating notice requires one subject-line pattern: the Chinese term for pre-consultation, then the applicant’s name, then the product name. Provincial regulators and CMDE both screen the file. An incomplete file is sent back with the problems identified. A file that passes goes to CMDE, which may convene an expert meeting.

The applicant must be the device manufacturer. At filing, the product must be finalized, the necessary nonclinical studies finished, and the protocol already written against the product’s features, clinical risk and existing clinical data. The package has to state the intended use, the operating or test principle, the structure or composition and materials where relevant, and the key functional and performance parameters, and it has to show that the expected clinical risk is acceptable. The applicant must keep the file true, accurate, complete and traceable, and must not withhold key technical information.

Except for products already in the innovative-device procedure, the same applicant may obtain the consultation no more than twice for the same product. CMDE’s opinion is guidance based on current scientific understanding and clinical consensus, not a technical-review conclusion. If the applicant changes the protocol afterward, the notice says the applicant should weigh the risk of that change. A material change in design or technical characteristics should be the occasion for a new request. The notice sets no response deadline.

For an overseas implant developer, Notice No. 40 still assigns the submission to the China agent, while the operating notice names CMDE’s mailbox as the destination and does not mention the agent. Until the original CMDE page and the mailbox attachment are in hand, those two sentences should be read together rather than treated as a repeal. The China Pharmaceutical News copy is titled as a CMDE notice and closes with a signature line for the National Medical Products Administration dated November 17, 2026.

## What this expands

The baseline remains CMDE’s March 6, 2026 notice on protocol pre-review for innovative medical devices, [reproduced by the China Association for Medical Devices Industry](http://www.camdi.cn/news/14543?ref=chinapharmadesk.com). That notice pointed applicants to the existing channel for major technical issues on innovative products. Notice No. 40 is the document that opens a route for products outside that procedure.

The March [device checklist](https://www.cmde.org.cn/directory/web/cmde/images/1773365357665069135.doc?ref=chinapharmadesk.com) covers control-group selection, eligibility, endpoints, follow-up, sample size and statistical methods. The [IVD checklist](https://www.cmde.org.cn/directory/web/cmde/images/1773365558569022348.doc?ref=chinapharmadesk.com) covers the biomarker rationale, the comparison method and positive-cutoff studies. The November 17 notice adds its own application forms for devices and for IVDs. Those forms were listed as attachments and were not read here, so the March checklists should not be assumed to be the new application package.

The consultation sits inside the wider [Chinese regulatory framework](https://chinapharmadesk.com/start-here/) as an optional pre-enrollment conversation with the national device evaluator. It is not a commitment that CMDE will answer by a stated date, and it is not available more than twice for an ordinary product.

The next documents are the CMDE original, the mailbox list and the two application forms. After January 1, 2027, the test is whether provinces post the same addresses outside that attachment and whether the first consultations actually run on this procedure.

*Updated November 17, 2026: Added CMDE’s operating notice, as reproduced by China Pharmaceutical News, including the mailbox split, the two-consultation cap and the dossier conditions. Notice No. 40’s overseas-agent route is retained because the new text does not withdraw it. The CMDE original file and the attachments were not retrieved.*